Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
Blood
|
August 25, 2001
Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis
H van der Kuip, A W Goetz, C Miething, et al.
Leukemia
|
March 16, 2002
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27
T Decker, F Schneller, S Hipp, et al.
Leukemia
|
February 19, 2011
In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease
N Hartmann, F Leithäuser, C Albers, et al.
Leukemia
|
September 13, 2003
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo
C Miething, C Mugler, R Grundler, et al.
Leukemia
|
September 25, 2014
Grb10 is involved in BCR-ABL-positive leukemia in mice
A L Illert, C Albers, S Kreutmair, et al.
Leukemia
|
April 6, 2016
Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype
T A Müller, R Grundler, R Istvanffy, et al.
Experimental Hematology
|
January 21, 2000
The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation
G Hübinger, I Scheffrahn, E Müller, et al.
Leukemia
|
February 17, 2006
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething, S Feihl, C Mugler, et al.
Oncogene
|
March 26, 2008
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells
S Fanta, M Sonnenberg, I Skorta, et al.
Oncogene
|
September 25, 1998
The SH2-containing adapter protein GRB10 interacts with BCR-ABL
R Y Bai, T Jahn, S Schrem, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
Blood
|
August 25, 2001
Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis
H van der Kuip, A W Goetz, C Miething, et al.
Leukemia
|
March 16, 2002
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27
T Decker, F Schneller, S Hipp, et al.
Leukemia
|
February 19, 2011
In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease
N Hartmann, F Leithäuser, C Albers, et al.
Leukemia
|
September 13, 2003
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo
C Miething, C Mugler, R Grundler, et al.
Leukemia
|
September 25, 2014
Grb10 is involved in BCR-ABL-positive leukemia in mice
A L Illert, C Albers, S Kreutmair, et al.
Leukemia
|
April 6, 2016
Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype
T A Müller, R Grundler, R Istvanffy, et al.
Experimental Hematology
|
January 21, 2000
The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation
G Hübinger, I Scheffrahn, E Müller, et al.
Leukemia
|
February 17, 2006
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething, S Feihl, C Mugler, et al.
Oncogene
|
March 26, 2008
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells
S Fanta, M Sonnenberg, I Skorta, et al.
Oncogene
|
September 25, 1998
The SH2-containing adapter protein GRB10 interacts with BCR-ABL
R Y Bai, T Jahn, S Schrem, et al.
Page
of 6